.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Personalizing the Path in mCRPC: Optimizing Chemotherapy and Aggressive Variant Prostate Cancer (AVPC)

EP. 1: The Role of Chemotherapy in Today’s mCRPC Landscape

November 14th 2025

Evolution of chemotherapy's role in metastatic castration-resistant prostate cancer treatment, including its positioning relative to ARPIs, PARP inhibitors, and targeted therapies, with discussion of treatment sequencing strategies and practical considerations for docetaxel use in high-volume versus low-volume disease.

EP. 2: Overcoming Barriers to Cabazitaxel and Optimizing Sequencing

November 14th 2025

Evidence-based approaches to cabazitaxel use in mCRPC, addressing treatment sequencing after prior therapies, real-world underutilization trends, patient counseling on benefits and risks, and FDA guidance on dosing strategies to optimize outcomes while managing toxicity.